Philogen (78Q) Stock Overview
A biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
78Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Philogen S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €22.10 |
| 52 Week High | €28.00 |
| 52 Week Low | €16.10 |
| Beta | 0.16 |
| 1 Month Change | 0.45% |
| 3 Month Change | -1.34% |
| 1 Year Change | 16.93% |
| 3 Year Change | 61.79% |
| 5 Year Change | n/a |
| Change since IPO | 50.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 78Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.8% | -1.0% | 0.7% |
| 1Y | 16.9% | -31.2% | 14.2% |
Return vs Industry: 78Q exceeded the German Biotechs industry which returned -31.2% over the past year.
Return vs Market: 78Q exceeded the German Market which returned 14.2% over the past year.
Price Volatility
| 78Q volatility | |
|---|---|
| 78Q Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 78Q has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 78Q's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 201 | Dario Neri | www.philogen.com |
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in Phase II trial for the treatment of non-small cell lung cancer. It is also developing Dekavil (F8IL10), an anti-inflammatory product in Phase II trial for the treatment of chronic inflammatory disorders; Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12, which is in Phase I trial to treat advanced solid tumors; OncoFAP radio conjugates, a small molecule radiotracer with ultra high affinity for fibroblast activation protein in Phase I trial for diagnostic and therapeutic applications of metastatic solid tumors; OncoACP3, a small molecule radiotracer with ultra high-affinity for acid phosphatase 3 in Phase I trial for diagnostic and therapeutic applications for prostate cancer; OncoCAIX, a small molecule radiotracer in Phase 1 trial for the detection of Carbonic Anhydrase IX (CAIX) expressed in renal cell carcinoma and other hypoxic tumors; and OncoFAP-GlyPro-MMAE, a small molecule drug conjugate with ultra-high affinity for fibroblast activation protein in preclinical trial for the treatment of solid tumors.
Philogen S.p.A. Fundamentals Summary
| 78Q fundamental statistics | |
|---|---|
| Market cap | €938.16m |
| Earnings (TTM) | €45.91m |
| Revenue (TTM) | €84.66m |
Is 78Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 78Q income statement (TTM) | |
|---|---|
| Revenue | €84.66m |
| Cost of Revenue | €24.64m |
| Gross Profit | €60.02m |
| Other Expenses | €14.11m |
| Earnings | €45.91m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.14 |
| Gross Margin | 70.89% |
| Net Profit Margin | 54.23% |
| Debt/Equity Ratio | 0.03% |
How did 78Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 07:56 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Philogen S.p.A. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Victor Floch | Stifel, Equities Research |
| Clemence Thiers | Stifel, Equities Research |